1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Britannia Life Sciences Inc.

Britannia Life Sciences Inc.

BLAB.CN
Britannia Life Sciences Inc.CA flagCanadian Securities Exchange
0.08
CAD
- -
- -
12.17MMarket Cap

Total Valuation

Britannia Life Sciences Inc. carries a market capitalization of 12.17M, placing it among publicly traded companies globally. Its enterprise value stands at -1.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.17M
Enterprise Value-1.03M

Share Statistics

Britannia Life Sciences Inc. currently has 162.25M shares outstanding.

Shares Outstanding162.25M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Britannia Life Sciences Inc. trades at a trailing price-to-earnings ratio of 0.71. The price-to-sales ratio is -3.37, and the price-to-book ratio stands at 0.98.

PE Ratio0.71
PS Ratio-3.37
PB Ratio0.98
P/TBV Ratio0.85
P/FCF Ratio-3.56
P/OCF Ratio-3.56

Financial Position

Britannia Life Sciences Inc. maintains a current ratio of 3.55, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.44, indicating moderate leverage, while an interest coverage ratio of 5.18 demonstrates adequate ability to service its debt obligations.

Current Ratio3.55
Quick Ratio3.44
Debt / Equity1.44
Debt / EBITDA-0.07
Interest Coverage5.18

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)92.65
Return on Invested Capital (ROIC)-19.43
Return on Capital Employed (ROCE)163.09
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover-13.92

Taxes

Over the trailing twelve months, Britannia Life Sciences Inc. has paid 1.48M in income taxes, reflecting an effective tax rate of 17.39.

Income Tax1.48M
Effective Tax Rate17.39

Stock Price Statistics

Britannia Life Sciences Inc.'s stock has gained approximately 7.14286% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.09.

Beta (5Y)N/A
52-Week Price Change7.14286%
50-Day Moving Average0.08
200-Day Moving Average0.09
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Britannia Life Sciences Inc. generated -4.33M in revenue and converted that into 20.49M in net income, yielding earnings per share of 0.04. EBITDA reached -3.74M, while operating income came in at -3.58M.

Revenue-4.33M
Gross Profit-2.98M
Operating Income-3.58M
Pretax Income8.50M
Net Income20.49M
EBITDA-3.74M
EBIT-3.58M
Earnings Per Share (EPS)0.04

Balance Sheet

Britannia Life Sciences Inc. holds 15.89M in cash and equivalents against 248,559.00 in total debt, resulting in a net debt position of -1.70M. Total book value stands at 14.84M, with working capital of 12.19M providing operational flexibility.

Cash & Cash Equivalents15.89M
Total Debt248,559.00
Net Debt-1.70M
Equity (Book Value)14.84M
Book Value Per Share0.09
Working Capital12.19M

Cash Flow

Britannia Life Sciences Inc. produced -4.10M in operating cash flow over the past twelve months.

Operating Cash Flow-4.10M
Capital ExpendituresN/A
Free Cash Flow-4.10M
FCF Per Share-0.03

Margins

Britannia Life Sciences Inc. operates with a gross margin of 68.80, reflecting its pricing power and cost economics. The operating margin of 82.58 and net profit margin of -472.89 provide insight into operational efficiency.

Gross Margin68.80
Operating Margin82.58
Pretax Margin-196.22
Profit Margin-472.89
EBITDA Margin86.26

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield9.29
FCF Yield-28.09

Stock Splits

Britannia Life Sciences Inc.'s most recent stock split took place on November 22, 2021 with a 10:1 split ratio.

Last Split Date11/22/2021
Split Ratio10:1

Scores

Britannia Life Sciences Inc. posts an Altman Z-Score of 1.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.60